Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 10/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538512 | 0.81 | PI4KA (0.77) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5111652 | 0.80 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL25310770 | 0.76 | PI4KA (0.68) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL19350813 | 0.75 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5118492 | 0.75 | PI4KA (0.51) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5105975 | 0.75 | YTHDC1 (0.54) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL28496042 | 0.75 | PI4KA (0.51) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5113125 | 0.73 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL28950113 | 0.71 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL9706194 | 0.70 | ADORA2A (0.35) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609656-B2 | Heteroarylphenylurea derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1724258-A1 | HETEROARYLPHENYLUREA DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHRM1, CBR3, CHRM2 | PI4KA 4459/4885PI4K2B 3789/4885PI4K2A 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.